Global Clinical Microbiology Instruments and Reagents Market to Reach $5.8 Billion by 2026

News provided by

Mar 24, 2022, 10:10 ET

SAN FRANCISCO , March 24, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Clinical Microbiology Instruments and Reagents - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

FACTS AT A GLANCE
What's New for 2022?

Global Clinical Microbiology Instruments and Reagents Market to Reach $5.8 Billion by 2026

Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Edition: 7; Released: February 2022

Executive Pool: 9152
Companies: 59 - Players covered include 3M; Abbott Laboratories; Agilent Technologies; Becton, Dickinson and Company; bioMérieux; Bio-Rad Laboratories, Inc; Bruker Corporation; Cepheid Inc; Danaher Corporation; Eiken Chemical Co., Ltd.; Hologic, Inc; NEOGEN Corporation; QIAGEN GmbH; Hoff Man Roche - Diagnostics Division ; Shimadzu Corporation; Thermo Fisher Scientific and Others.
Coverage: All major geographies and key segments
Segments: Product (Instruments, Reagents); Disease Area (Respiratory Diseases, Bloodstream Infections, Gastrointestinal Diseases, Sexually Transmitted Diseases, Urinary Tract Infections, Other Disease Areas); End-Use (Hospitals & Diagnostic Centers, Custom Lab Service Providers, Academic & Research Institutes)
Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry

ABSTRACT-

Global Clinical Microbiology Instruments and Reagents Market to Reach $5.8 Billion by 2026
Clinical microbiology holds a prominent role in the field of research and medicine, and support the fight against numerous infectious diseases along with antimicrobial resistance. High prevalence of infectious diseases and sexually transmitted diseases (STDs) will continue to drive the future of automated and rapid tests, as the need for quicker, higher volume and more accurate methods of testing gains significance. Emerging technologies and robust processes have thus transcended microbiology testing to the next-level. Rising healthcare expenditure, growing need to speed up microbiological testing, scarcity of time, need for rapid QA-QC procedures, and growing imposition of regulations that regulate various production processes are factors that have catalyzed this transformation. The uptake of microbiology is further favored by technological advancements including automated instruments to identify pathogens across laboratories. The trend towards automated instrumentation is aided by the promise of overall cost effectiveness and efficiency. Another driver for the market growth is consolidation of laboratories and rising consumer awareness.

Amid the COVID-19 crisis, the global market for Clinical Microbiology Instruments and Reagents estimated at US$4.5 Billion in the year 2022, is projected to reach a revised size of US$5.8 Billion by 2026, growing at a CAGR of 6.4% over the analysis period. Instruments, one of the segments analyzed in the report, is projected to record 5.3% CAGR and reach US$2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Reagents segment is readjusted to a revised 7.1% CAGR for the next 7-year period. Growth in the Reagents segment is due to increasing aging population that is vulnerable to microbial infections and chronic conditions such as bacterial pneumonia, urinary tract infections, gastrointestinal issues, renal diseases and cancer. The market growth is slated to be augmented by outbreaks of pandemics including COVID-19, Ebola and Zika virus, leaving a large number of infected people.

The U.S. Market is Estimated at $1.7 Billion in 2022, While China is Forecast to Reach $284.1 Million by 2026
The Clinical Microbiology Instruments and Reagents market in the U.S. is estimated at US$1.7 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$284.1 Million by the year 2026 trailing a CAGR of 7.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR. The US and Europe constitute major markets for automated and rapid microbiological tests. Emerging nations, such as China, India, and Brazil, present significant opportunities due to their constantly growing healthcare infrastructure. Aging population and rising incidence of chronic illnesses and lifestyle diseases are spurring spending on health services and clinical lab services. The Asian market presents substantial growth opportunities owing to rising prevalence of various pathogenic diseases, requirement to accelerate microbiological testing and discovery of adapting and mutating bacterium. More

MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android

About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
Email: [email protected]

LINKS
Join Our Expert Panel
https://www.strategyr.com/Panelist.asp

Connect With Us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./

Follow Us on Twitter
https://twitter.com/marketbytes

Journalists & Media
[email protected]

SOURCE Global Industry Analysts, Inc.